Journal
PLACENTA
Volume 84, Issue -, Pages 44-49Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2019.04.007
Keywords
Preeclampsia; Kynurenine pathway; Vascular dysfunction; Immunoregulation
Funding
- Wellbeing of Women [ELS083]
- Medical Research Council / Royal College of Obstetricians and Gynaecologists [MR/N020685/1]
- MRC [MR/N020685/1] Funding Source: UKRI
Ask authors/readers for more resources
In preeclampsia, vasospasm, oxidative stress, endothelial dysfunction, and immune dysregulation are key mediators of maternal disease. A new time-of-disease treatment is needed with the potential to treat these areas of pathophysiology. A review of the literature has indicated that metabolites of the kynurenine pathway have the potential to; (i) induce vasorelaxation of resistance arteries and reduce blood pressure; (ii) exert antioxidant effects and reduce the effects of poly-ADP ribose polymerase activation (iii) prevent endothelial dysfunction and promote endothelial nitric oxide production; (iv) cause T cell differentiation into tolerogenic regulatory T cells and induce apoptosis of pro-inflammatory Th1 cells. This has led to the hypothesis that increasing Kynurenine pathway activity may offer a new treatment strategy for preeclampsia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available